OBJECTIVE -We studied differences between patients with latent autoimmune diabetes in adults (LADA), type 2 diabetes, and classical type 1 diabetes diagnosed after age 35 years.
P
atients with latent autoimmune diabetes in adults (LADA) have a progressive insulin secretion defect, have less evidence of metabolic syndrome than type 2 patients, and share a genetic predisposition with both type 1 and type 2 diabetic patients (1) (2) (3) (4) (5) . Whether LADA merely represents older-onset type 1 diabetes or is a distinct subgroup has been debated (6) , but studies comparing LADA with classical type 1 diabetes in a comparative age-range are lacking. We investigated 1 ) whether LADA differed genetically (with respect to genes associated with risk of type 1 diabetes: HLA-DQB1, PTPN22, INS, and CTLA4) and phenotypically (with respect to metabolic syndrome) from type 1 diabetes diagnosed after age 35 years; and 2) whether the observed clinical heterogeneity within LADA depended on GAD antibody (GADA) levels and type 1 diabetes susceptibility genotypes.
RESEARCH DESIGN AND METHODS -We included patients with age at onset Ͼ35 years with LADA (defined here as GADA-positive diabetes without insulin treatment for the first 6 months; n ϭ 213) or with type 1 diabetes (T1D Ͼ35y ; n ϭ 35), patients with type 1 diabetes diagnosed at Ͻ20 years of age (T1D Ͻ20y ; n ϭ 158), and GADApositive type 2 diabetic patients (n ϭ 648) from the Botnia study (2) together with T1D Ͼ35y patients (n ϭ 222) from the FinnDiane study (7) . The noninsulin-treated subjects underwent an oral glucose tolerance test with blood samples drawn at Ϫ5, 0, 30, 60, and 120 min for measurement of plasma glucose, serum insulin, C-peptide, lipids, and GADA levels (8) . The HLA-DQB1*02, *0301, *0302, *0602, and *0603 alleles were genotyped (9) and classified as risk (*0302/*02, 0302/X), protective [*0602(3)/X, *0602(3)/ *0301], or neutral (all other) (X ϭ homozygous or other allele). The INS Ϫ Hph23 A/T (rs689), CTLA4 CT60 (rs3087243), and PTPN22 1858CϾT (rs2476601) variants were genotyped with TaqMan allelic discrimination (Applied Biosystems, Foster City, CA). Statistical analyses were performed with Statistical Package for Social Science software (version 13.0; SPSS, Chicago, IL) using the 2 test, the Kruskal-Wallis test, or a general linear model. Participants gave informed consent, and the study was approved by the local ethics committee.
RESULTS -The HLA-DQB1 risk genotypes were most frequent in T1D Ͻ20y patients (75.3%), followed by T1D Ͼ35y patients (50.2%) and LADA patients (32.2%) (P Ͻ 0.00001; Fig. 1 ), with the opposite trend for the protective genotypes. The type 1 diabetic patients also had a higher frequency of the PTPN22 risk allele (T1D Ͻ20y 17.7% and T1D Ͼ35y 21.1%) than LADA patients (14.5%; P ϭ 0.008). Compared with type 2 diabetes, the HLA-DQB1 (P Ͻ 0.00001) and PTPN22 risk genotypes and alleles (P ϭ 0.04 -0.008) were significantly more common in LADA. The INS and CTLA4 risk genotypes were only associated with type 1 diabetes (T1D Ͼ35y , LADA, type 2 diabetes: INS 77.4, 58.7, and 56.5%, re- All risk genotypes and alleles were most prevalent in patients in the highest GADA quartile (LADA high , GADA Ͼ278 IU/ml) compared with the two middle (LADA mid , 44 -278 IU/ml) or the lowest quartiles (LADA low , 33-43.9 IU/ml; Fig.  1 ), but the difference was significant only for HLA-DQB1 (P ϭ 0.009). However, even LADA high subjects differed from T1D Ͼ35y subjects (P ϭ 0.001), and LADA low subjects had nonsignificantly more HLA-DQB1 risk genotypes than type 2 diabetic subjects (19.6 vs. 14.0%). LADA high subjects also differed from the type 2 diabetic subjects with respect to the allele frequency of PTPN22 (P ϭ 0.02) and CTLA4 (P ϭ 0.03).
In a joint analysis of the four genes, two or more risk genotypes were most common in T1D Ͻ20y patients (82.1%), followed by T1D Ͼ35y patients (74.4%), LADA (54.1%), and type 2 diabetic (38.7%) patients (P Ͻ 0.00001). The frequency differed across the GADA quartiles (P ϭ 0.004), and it was similar in LADA high and T1D Ͼ35y patients (72.5 vs. 74.4%), as well as in LADA low and type 2 diabetic patients (46.0 vs. 38.7%) (online appendix Table A3 , available at http:// care.diabetesjournals.org/cgi/content/full/ dc09-2188/DC1). LADA patients with an increasing number of risk genotypes had decreasing fasting serum (fS)-C-peptide concentrations (P ϭ 0.015).
The LADA patients had higher BMI and lipid concentrations than the T1D Ͼ35y patients (online appendix Table  A1 ). Compared with type 2 diabetic patients, LADA patients had lower insulin secretion and BMI, as well as a better lipid profile. Going from LADA low to LADA high , there was a significant trend toward lower insulin secretion, lipid levels, and BMI (online appendix Table A2 ). However, the fS-C-peptide concentration was higher in LADA high patients compared with T1D Ͼ35y patients and was somewhat lower in LADA low compared with type 2 diabetic patients. Despite the marked age difference, the T1D Ͼ35y and T1D Ͻ20y patients were metabolically similar.
CONCLUSIONS -We have shown a significant genetic difference between LADA and type 1 diabetes diagnosed after age 35 years. Although HLA-DQB1 and PTPN22 risk genotypes were increased in LADA, they were much less common than in type 1 diabetes. INS and CTLA4 were only associated with type 1 diabetes.
As suggested previously (3,5,10), genetic differences and clinical phenotype were associated with GADA levels, explaining some of the observed heterogeneity within LADA. Of note, the LADA high group (GADA Ͼ278 IU/ml) roughly corresponds to the high GADA group (Ͼ300 IU/ml) in the Non Insulin Requiring Autoimmune Diabetes (NIRAD) Study, in which association with PTPN22 was also found only in patients with high GADA (10).
Our study is the largest to date in adult-onset type 1 diabetic patients. In agreement with a smaller study (11) , we clearly showed a lower frequency of DQB1 risk genotypes in T1D Ͼ35y compared with T1D Ͻ20y patients. However, protective HLA-DQB1 genotypes were as (4, 14, 15) , the INS variant was not associated with LADA in the Finnish subjects.
In conclusion, we have shown that patients with LADA differ genetically and phenotypically from type 1 diabetic patients diagnosed after age 35 years. The LADA group was heterogeneous, and both the genotype distribution and phenotypic characteristics were associated with GADA level. A significant trend was observed toward lower insulin secretion and metabolic trait values going from the lowest GADA quartile to the highest. Thus, LADA patients with high GADA concentrations were more similar, but not identical, to type 1 diabetic patients, and those with low GADA concentrations were more similar to type 2 diabetic patients.
